Histological assessment of cardiac amyloidosis in patients undergoing transcatheter aortic valve replacement.
Aortic stenosis
Cardiac amyloidosis
Congo red staining
Histology
Sudden cardiac death
TAVR
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
26 Feb 2024
26 Feb 2024
Historique:
revised:
28
11
2023
received:
27
06
2023
accepted:
19
01
2024
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
26
2
2024
Statut:
aheadofprint
Résumé
Studies have reported a strongly varying co-prevalence of aortic stenosis (AS) and cardiac amyloidosis (CA). We sought to histologically determine the co-prevalence of AS and CA in patients undergoing transcatheter aortic valve replacement (TAVR). Consequently, we aimed to derive an algorithm to identify cases in which to suspect the co-prevalence of AS and CA. In this prospective, monocentric study, endomyocardial biopsies of 162 patients undergoing TAVR between January 2017 and March 2021 at the University Medical Centre Göttingen were analysed by one pathologist blinded to clinical data using haematoxylin-eosin staining, Elastica van Gieson staining, and Congo red staining of endomyocardial biopsies. CA was identified in only eight patients (4.9%). CA patients had significantly higher N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (4356.20 vs. 1938.00 ng/L, P = 0.034), a lower voltage-to-mass ratio (0.73 vs. 1.46 × 10 The co-prevalence of AS and CA was lower than expected, at 4.9%. Despite excellent 1 year mortality, AS + CA patients died significantly more often from SCD. We propose a multimodal algorithm to facilitate more effective screening for CA containing parameters commonly documented during clinical routine. Proteomic biomarkers may yield additional information in the future.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : CRC 1002, D1
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357-1377. doi:10.1161/CIRCULATIONAHA.116.024438
Rossi M, Varrà GG, Porcari A, Saro R, Pagura L, Lalario A, et al. Re-definition of the epidemiology of cardiac amyloidosis. Biomedicine 2022;10:1566.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-1016. doi:10.1056/NEJMoa1805689
Tanskanen M, Peuralinna T, Polvikoski T, Notkola I, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med 2008;40:232-239. doi:10.1080/07853890701842988
Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-2887. doi:10.1093/eurheartj/ehx350
Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 2016;9:e005066. doi:10.1161/CIRCIMAGING.116.005066
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561-632. doi:10.1093/eurheartj/ehab395
Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States. Circ Heart Fail 2019;12:e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407
Abecasis J, Lopes P, Santos RR, Maltês S, Guerreiro S, Ferreira A, et al. Prevalence and significance of relative apical sparing in aortic stenosis: Insights from an echo and cardiovascular magnetic resonance study of patients referred for surgical aortic valve replacement. Eur Heart J Cardiovasc Imaging 2023;24:jead032. doi:10.1093/ehjci/jead032
Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:909-920. doi:10.1016/j.jcmg.2019.10.011
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554-1568. doi:10.1093/eurheartj/ehab072
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-2791. doi:10.1093/eurheartj/ehx391
Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation. J Am Coll Cardiol 2012;60:1438-1454. doi:10.1016/j.jtcvs.2012.09.002
Kligfield P, Gettes LS, Bailey JJ, Childers R, Deal BJ, Hancock EW, et al. Recommendations for the standardization and interpretation of the electrocardiogram. J Am Coll Cardiol 2007;49:1109-1127. doi:10.1161/CIRCULATIONAHA.106.180200
Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 2021;77:128-139. doi:10.1016/j.jacc.2020.11.006
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-271. doi:10.1093/ehjci/jew041
Beuthner BEC, Topci R, Derks M, Franke T, Seelke S, Puls M, et al. Interdisciplinary research on aortic valve stenosis: A longitudinal collection of biospecimens and clinical data of patients undergoing transcatheter aortic valve replacement. Open J Bioresour 2020;7:3. doi:10.5334/ojb.65
Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-1607. doi:10.1056/NEJMoa1008232
Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-1620. doi:10.1056/NEJMoa1514616
Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 2017;19:98. doi:10.1186/s12968-017-0415-x
Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: Prevalence, screening possibilities, and outcome. Eur J Heart Fail 2020;22:1852-1862. doi:10.1002/ejhf.1756
Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental Western Europe: An insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J 2022;43:391-400. doi:10.1093/eurheartj/ehz173
Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume. J Am Coll Cardiol 2005;45:87-92. doi:10.1016/j.jacc.2004.09.054
Saito Y, Lewis EE, Raval A, Gimelli G, Jacobson K, Osaki S. Prognosis of paradoxical low-flow low-gradient aortic stenosis after transcatheter aortic valve replacement. J Cardiovasc Med 2021;22:486-491. doi:10.2459/JCM.0000000000001139
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-2412. doi:10.1161/CIRCULATIONAHA.116.021612
Dang J, Abulizi M, Moktefi A, El Karoui K, Deux JF, Bodez D, et al. Renal infarction and its consequences for renal function in patients with cardiac amyloidosis. Mayo Clin Proc 2019;94:961-975. doi:10.1016/j.mayocp.2019.02.012
Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012;7:1337-1346. doi:10.2215/CJN.08720811
Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, et al. Amyloidosis. Orphanet J Rare Dis 2012;7:54. doi:10.1186/1750-1172-7-54
Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int 2008;73:538-546. doi:10.1038/sj.ki.5002743
Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, et al. Holter monitoring in AL amyloidosis: Prognostic implications. Pacing Clin Electrophysiol 2001;24:1228-1233. doi:10.1046/j.1460-9592.2001.01228.x
Rezaei-Ghaleh N, Zweckstetter M, Morshedi D, Ebrahim-Habibi A, Nemat-Gorgani M. Amyloidogenic potential of α-chymotrypsin in different conformational states. Biopolymers 2009;91:28-36. doi:10.1002/bip.21079
Garcia-Pardo J, Graña-Montes R, Fernandez-Mendez M, Ruyra A, Roher N, Aviles FX, et al. Amyloid formation by human carboxypeptidase D transthyretin-like domain under physiological conditions. J Biol Chem 2014;289:33783-33796. doi:10.1074/jbc.M114.594804
Tanaka T, Lavery R, Varma V, Fantoni G, Colpo M, Thambisetty M, et al. Plasma proteomic signatures predict dementia and cognitive impairment. Alzheimers Dement N Y N 2020;6:e12018. doi:10.1002/trc2.12018